Short and long-term impacts of AAV process optimization on your gene therapy pipeline

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

High yield, high quality, and high-efficiency AAV production is essential for advancing gene therapy. Producing enough viral particles in a cost-effective way for medium to high dose indications, and moderate to large prevalence diseases poses significant challenges.

To meet demand, manufacturers often scale out and scale-up, investing in facilities, equipment, and personnel. Upstream process optimization offers a key solution to increase overall yields and alleviate capacity constraints while removing economic barriers as processes move from the clinic to commercialization.

This webinar will explore the applying an economic model to quantify the impact of upstream process optimization with varying transfection technologies using real-world case studies. We will evaluate fold improvements in AAV titer, percent full capsids, batch cost, and cost-per dose comparisons.

Considerations for changing processes supporting early clinical AAV assets will be discussed from economic and practical viewpoints. Further, long range economic modelling will demonstrate the impact of decisions made during process development on commercial manufacturing. Lastly, webinar participants will have the opportunity to witness simulations in real-time with a new AAV manufacturing cost calculator.

Attend this webinar to learn about:

• A case study which demonstrates how to reduce cost per dose and overall cost of investment by optimizing upstream AAV processes for AAV titer and percent full capsids
• How a CMDO is able to reduce their cost per dose using AAV transfection systems
• Utilizing an AAV manufacturing cost calculator to customize results for process developments

Fletcher Malcom

Director of Strategy, Product and Business Development at Mirus Bio

Fletcher is a creative biotech industry professional with subject matter expertise in product strategy and bringing new products to market. In his current role, he leads the strategy, product management, and business development functions at Mirus Bio.

Previous to his role at Mirus Bio, Fletcher was Head of Product at Nanopareil where he designed and executed product strategy. Prior to Nanopareil he helped develop and launch Repligen’s OPUS® pre-packed column product line in 2012 and spent 9 years building the business into the market segment leader. From 2012-2021, Fletcher spearheaded more than 10 go-to-market product launch campaigns and worked closely with end-users to implement the technology for cGMP applications. Passionate about new technology, Fletcher is driven by his vision of delivering transformative products to the bioprocessing industry. He holds a BA in chemistry from Hamilton College and an MBA from Babson College.

in 23

Days

Register

SPEAKERS

Fletcher Malcom

Director of Strategy, Product and Business Development at Mirus Bio

You might also like

Engineering next-generation CAR-T cell therapy for cancer

Yvonne Chen

21 August

in 37

Days

Register

Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

Nikki Votaw

20 August

in 36

Days

Register

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

J Aho, A Conerty, S Shields et al.

15 August

in 31

Days

Register

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Monica Raimo, Jan Spanholtz

6 August

in 22

Days

Register

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya

1 August

in 17

Days

Register